This episode of the VJHemOnc podcast features an exclusive expert-led roundtable discussion summarizing two sessions from the 8th International Workshop on Acute Leukemias (iwAL 2026) that focused on novel targets, combinations, and treatments in acute myeloid leukemia (AML). This session is chaired by Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, who is joined by panelists Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France. The experts explore the evolving genetic classification of AML and the nuances of TP53, the move from azacitidine and venetoclax toward molecularly guided triplets, emerging strategies to overcome menin inhibitor resistance and target TP53-mutated disease, and the promise of an all-oral regimen in this malignancy.